G1 reports Phase IIa data for trilaciclib as first-line treatment of SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) reported top-line data from 77 treatment-naïve patients with extensive-stage small cell lung cancer (SCLC) in the double-blind Phase IIa portion of the international Phase Ib/IIa G1T28-02 trial showing that first-line treatment with IV trilaciclib (G1T28) plus etoposide and carboplatin led to an overall response rate (ORR) of 66.7% vs. 62.2% for placebo plus etoposide and carboplatin (p=0.6759). Median progression-free survival (PFS) was 6.2 months for trilaciclib plus chemotherapy vs. 5 months for placebo plus chemotherapy (HR=0.6, p=0.06).

Trilaciclib was well tolerated with no grade 3/4 treatment-related adverse events reported. G1 also said trilaciclib reduced "clinically relevant consequences" of chemotherapy-induced myelosuppression vs. placebo...